乾癬市場:日本の治療薬市場

◆英語タイトル:Psoriasis - Japan Drug Forecast and Market Analysis to 2024
◆商品コード:GDHC279CFR
◆発行会社(調査会社):GlobalData
◆発行日:2016年4月13日
◆ページ数:210
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:日本
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD4,995 ⇒換算¥554,445見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD9,990 ⇒換算¥1,108,890見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD14,985 ⇒換算¥1,663,335見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Psoriasis – Japan Drug Forecast and Market Analysis to 2024
Summary

Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients.

GlobalData projects the Psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-17 (IL-17) inhibitors (Cosentyx, guselkumab and tildrakizumab), interleukin-23 (IL-23) inhibitors (ixekizumab and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs- especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developmentsof biosimilars are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.

Japan has not approved Amgen’s Enbrel for the treatment of psoriasis, and we expect this to remain so. However, Humira, Stelara, and more recently, Cosentyx are strong choices as branded drugs in Japan. Humira and Stelara are both expected to go off-patent in 2017 and 2021, respectively, while Cosentyx is expected to remain patented well past the forecast period end.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Overview of Psoriasis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting Japan Psoriasis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in Japan.

【レポートの目次】

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Leading Prescribed Drugs and Treatment Guidelines
4.1.3 Clinical Practice
4.2 Japan
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles – Major Brands
5.3.1 Enbrel (Etanercept)
5.3.2 Humira (Adalimumab)
5.3.3 Remicade (Infliximab)
5.3.4 Stelara (ustekinumab)
5.3.5 Cosentyx (Secukinumab)
5.3.6 Otezla (Apremilast)
5.3.7 Taclonex and Enstilar (Calcipotriene and Betamethasone Dipropionate)
5.3.8 Methotrexate
5.3.9 Fumaderm (Fumaric Acid Esters)
5.3.10 Alzumab (itolizumab)
5.3.11 Other Therapeutic Drug Classes Used in Psoriasis
5.3.12 Non-pharmacological Therapy
6 Unmet Need and Opportunity
6.1 Overview
6.2 Limited Patient Access Due to Drug Reimbursement Pattern
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Improved Drug Safety and Efficacy Profiles
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Education and Treatment of Psychological Factors Accompanying Psoriasis
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Clinical Trial Mapping
7.2.1 Clinical Trials by Country
7.3 Clinical Trials by Phase and Trial Status
7.4 Promising Drugs in Clinical Development
7.4.1 Xeljanz (Tofacitinib)
7.4.2 Ixekizumab (LY2439821)
7.4.3 Brodalumab
7.4.4 Guselkumab (CNTO-1959)
7.4.5 Tildrakizumab
7.4.6 Piclidenoson (CF-101)
7.4.7 Additional Phase III Pipeline Products
7.4.8 Phase II Pipeline Products
7.4.9 Phase I Pipeline Products
7.5 Biosimilar Pipeline Products
7.5.1 Introduction
7.5.2 Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases
7.5.3 Biosimilars in the Immunology Community
7.5.4 By the Numbers: Biosimilars in Development
7.5.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry
7.5.6 Uptake of Biosimilars for Psoriasis is Expected to Vary by Market
7.5.7 Biosimilars Forecast
8 Market Outlook
8.1 Japan
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Psoriasis Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline agents
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research – Prescriber Survey
9.7 About the Authors
9.7.1 Author
9.7.2 Reviewer
9.7.3 Epidemiologist
9.7.4 Global Director of Therapy Analysis and Epidemiology
9.7.5 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer

1.1 List of Tables
Table 1: Immune Cells Involved in Lesions
Table 2: Symptoms of Psoriasis
Table 3: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis
Table 4: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, 2014
Table 5: Treatment Guidelines for Psoriasis
Table 6: Country Profile - Japan
Table 7: Leading Treatments for Psoriasis, 2015
Table 8: Product Profile - Enbrel
Table 9: Enbrel Pivotal Study I Outcomes at 3 and 6 Months
Table 10: Enbrel pivotal study II outcomes at 3 Months
Table 11: Long-Term Studies on Enbrel Efficacy in Treatment of Psoriasis
Table 12: Long-Term Safety Profile of Enbrel in the Treatment of Psoriasis
Table 13: Enbrel SWOT Analysis, 2015
Table 14: Global Sales Forecast ($m) for Enbrel, 2014-2024
Table 15: Product Profile - Humira
Table 16: Humira pivotal study outcomes at 16 weeks
Table 17: Humira SWOT Analysis, 2015
Table 18: Global Sales Forecast ($m) for Humira, 2014-2024
Table 19: Product Profile - Remicade
Table 20: Efficacy Results of RESTORE1 Trial of Remicade vs. MTX at Week 26
Table 21: Safety Results and AEs of RESTORE1 Trial of Remicade vs. MTX at Week 16
Table 22: Remicade SWOT Analysis, 2015
Table 23: Global Sales Forecast ($m) for Remicade, 2014-2024
Table 24: Product Profile - Stelara
Table 25: Stelara Pivotal Study Outcomes at Week 12
Table 26: Stelara SWOT Analysis, 2015
Table 27: Global Sales Forecast ($m) for Stelara, 2014-2024
Table 28: Product Profile - Cosentyx
Table 29: Efficacy Endpoints in Cosentyx Phase III ERASURE Study
Table 30: Efficacy End Points in Cosentyx Phase III FIXTURE study
Table 31: Cosentyx SWOT Analysis, 2015
Table 32: Global Sales Forecast ($m) for Cosentyx, 2014-2024
Table 33: Product Profile - Otezla
Table 34: Otezla Efficacy Results at Week 16 in Studies ESTEEM-1 and ESTEEM-2
Table 35: Otezla SWOT Analysis, 2015
Table 36: Global Sales Forecast ($m) for Otezla, 2014-2024
Table 37: Product Profile - Taclonex/Enstilar
Table 38: Taclonex Efficacy Outcomes from Pivotal Phase III Studies for Adult Scalp and Body Psoriasis.
Table 39: Taclonex/Enstilar SWOT Analysis, 2015
Table 40: Global Sales Forecast ($m) for Taclonex/Daivobet/Dovobet, 2014-2024
Table 41: Product Profile - Methotrexate
Table 42: Methotrexate SWOT Analysis, 2015
Table 43: Global Sales Forecast ($m) for Methotrexate, 2014-2024
Table 44: Product Profile - Fumaderm
Table 45: Fumaderm SWOT Analysis, 2015
Table 46: Global Sales Forecast ($m) for Fumaderm, 2014-2024
Table 47: Product Profile - Alzumab
Table 48: Alzumab SWOT Analysis, 2013
Table 49: Global Sales Forecast ($m) for Alzumab, 2014-2024
Table 50: Summary of Minor Therapeutic Drug Classes for Psoriasis, 2015
Table 51: Dosing Guidelines for Broadband Ultraviolet B
Table 52: Dosing Guidelines for Narrowband Ultraviolet B
Table 53: Overall Unmet Needs in Psoriasis - Current Level of Attainment
Table 54: Psoriasis - Clinical Trials by Phase and Status, 2015
Table 55: Psoriasis - Phase Pipeline, 2015
Table 56: Comparison of Therapeutic Classes in Development for Psoriasis, 2015
Table 57: Product Profile - Xeljanz
Table 58: Xeljanz SWOT Analysis, 2015
Table 59: Global Sales Forecast ($m) for Xeljanz, 2014-2024
Table 60: Product Profile - Ixekizumab
Table 61: Efficacy Results of UNCOVER-2 at Week 12
Table 62: Efficacy Results of UNCOVER-3 at Week 12
Table 63: Ixekizumab SWOT Analysis, 2015
Table 64: Global Sales Forecast ($m) for Ixekizumab, 2014-2024
Table 65: Product Profile - Brodalumab
Table 66: Brodalumab SWOT Analysis, 2015
Table 67: Global Sales Forecast ($m) for Brodalumab, 2014-2024
Table 68: Product Profile - Guselkumab
Table 69: Guselkumab SWOT Analysis, 2015
Table 70: Global Sales Forecast ($m) for Guselkumab, 2014-2024
Table 71: Product Profile - Tildrakizumab
Table 72: Tildrakizumab SWOT Analysis, 2015
Table 73: Global Sales Forecast ($m) for Tildrakizumab, 2014-2024
Table 74: Product Profile - Piclidenoson (CF-101)
Table 75: Piclidenoson SWOT Analysis, 2015
Table 76: Additional Phase III Psoriasis Pipeline drugs, 2015
Table 77: Phase II Psoriasis Pipeline, 2015
Table 78: Phase I Psoriasis Pipeline, 2015
Table 79: Marketed and Pipeline Biosimilars for Psoriasis in the 8MM, 2015
Table 80: Physician Uptake of Biosimilar Products for Psoriasis Across the 8MM, 2015
Table 81: Global Sales Forecast ($m) for Etanercept Biosimilars, 2014-2024
Table 82: Global Sales Forecast ($m) for Adalimumab Biosimilars, 2014-2024
Table 83: Global Sales Forecast ($m) for Infliximab Biosimilars, 2014-2024
Table 84: Sales Forecast ($) for Psoriasis in Japan, 2014-2024
Table 85: Key Events Impacting Sales for Psoriasis in Japan, 2014-2024
Table 86: Psoriasis Market in Japan - Drivers and Barriers, 2014-2024
Table 87: Key Launch Dates
Table 88: Key Patent Expiries
Table 89: Key Launch Dates
Table 90: Physicians Surveyed, by Country

1.2 List of Figures
Figure 1: Psoriatic Plaque on Elbow of Patient
Figure 2: The Three Layers of the Skin and Associated Structures
Figure 3: Healthy Skin Versus Psoriatic Skin
Figure 4: Psoriasis Therapeutics - Ongoing Clinical Trial Sites by Country, 2015
Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Psoriasis, 2014-2024
Figure 6: Biosimilar Prescribing Habits in Psoriasis Across the 8MM, 2015
Figure 7: Global Sales Forecast ($m) for Enbrel vs. Etanercept Biosimilars, 2014-2024
Figure 8: Global Sales Forecast ($m) for Humira vs. Adalimumab Biosimilars, 2014-2024
Figure 9: Global Sales Forecast ($m) for Remicade vs. Infliximab Biosimilars, 2014-2024
Figure 10: Sales for Psoriasis in Japan by Drug Class, 2014-2024

★調査レポート[乾癬市場:日本の治療薬市場]販売に関する免責事項
★調査レポート[乾癬市場:日本の治療薬市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆